MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s stock price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $16.99 and traded as high as $17.55. MediWound shares last traded at $17.44, with a volume of 97,816 shares changing hands.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on MDWD shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of MediWound in a research report on Tuesday, April 21st. Wall Street Zen downgraded MediWound from a "hold" rating to a "strong sell" rating in a research report on Saturday, March 7th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MediWound currently has an average rating of "Hold" and a consensus target price of $35.00.
View Our Latest Stock Report on MediWound
MediWound Price Performance
The stock has a 50-day simple moving average of $16.99 and a 200-day simple moving average of $17.70. The stock has a market cap of $224.10 million, a PE ratio of -8.30 and a beta of 0.21.
MediWound (NASDAQ:MDWD - Get Free Report) last posted its quarterly earnings results on Saturday, February 14th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. MediWound had a negative net margin of 140.80% and a negative return on equity of 65.79%. The firm had revenue of $1.87 million for the quarter. As a group, equities research analysts anticipate that MediWound Ltd. will post -2.75 EPS for the current year.
Institutional Investors Weigh In On MediWound
Institutional investors have recently added to or reduced their stakes in the company. Meitav Investment House Ltd. grew its position in MediWound by 825.7% during the third quarter. Meitav Investment House Ltd. now owns 291,618 shares of the biopharmaceutical company's stock valued at $5,241,000 after acquiring an additional 260,116 shares during the period. Clal Insurance Enterprises Holdings Ltd purchased a new stake in MediWound during the third quarter valued at about $1,042,000. Menora Mivtachim Holdings LTD. grew its position in MediWound by 348.8% during the third quarter. Menora Mivtachim Holdings LTD. now owns 78,539 shares of the biopharmaceutical company's stock valued at $1,415,000 after acquiring an additional 61,039 shares during the period. Rosalind Advisors Inc. grew its position in MediWound by 84.0% during the third quarter. Rosalind Advisors Inc. now owns 749,054 shares of the biopharmaceutical company's stock valued at $13,498,000 after acquiring an additional 341,993 shares during the period. Finally, Deutsche Bank AG grew its position in MediWound by 79.6% during the fourth quarter. Deutsche Bank AG now owns 7,971 shares of the biopharmaceutical company's stock valued at $147,000 after acquiring an additional 3,532 shares during the period. Hedge funds and other institutional investors own 46.83% of the company's stock.
MediWound Company Profile
(
Get Free Report)
MediWound Ltd. NASDAQ: MDWD is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.
The company's lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MediWound, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MediWound wasn't on the list.
While MediWound currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
